Re: 만성폐쇄성 폐질환(COPD) 기관지 확장 한약재 탐구!!

[문형철]

연구 목적 및 배경

안정기 COPD(만성 폐쇄성 폐질환) 환자에서 전통 중의학(TCM, 주로 중약(CHM)과 침술 조합)을 기존 서양의학 치료(Conventional Treatment, CT)에 보조적으로 사용했을 때의 임상 효과와 안전성을 평가하기 위한 체계적 문헌고찰 및 메타분석. 이전 연구들은 CHM이나 침술을 단독으로 평가했으나, 실제 TCM 임상처럼 CHM과 침술을 결합한 통합 접근을 중점으로 분석. COPD는 전 세계 사망 원인 상위권 질환으로, 증상 완화와 급성 악화 예방이 치료 목표.

방법

• 연구 디자인: PRISMA 지침 준수 체계적 고찰 및 메타분석 (PROSPERO 등록: CRD42019161324).
• 포함 기준: 이중맹검 RCT만 포함, 안정기 COPD 환자(≥18세, GOLD 기준 진단), TCM(CHM ± 침술) + CT vs. CT 단독.
• 검색: PubMed, EMBASE, CNKI 등 다수 데이터베이스 (2019년 11월까지).
• 포함 연구: 100개 RCT (총 8,291명 참가자), 대부분 중국 단일 센터 연구, 샘플 크기 작음(15~83명/arm).
• 주요 평가 지표:
  • Primary: 폐기능(FEV₁), 급성 악화율, CAT 점수, 부작용.
  • Secondary: 삶의 질(QoL), TCM 증후 점수 및 유효율, 6분 보행거리(6MWD).
• 분석: Random-effects 모델, GRADE로 증거 질 평가.

주요 결과

• 폐기능(FEV₁): 40개 연구 → TCM 보조군에서 평균 0.18L 증가 (MD 0.18, 95% CI 0.08~0.28, p<0.001).
• 급성 악화율: 13개 연구 → 감소 경향 (MD -0.29, 95% CI -0.61~0.03, p=0.075, 비유의).
• CAT 점수: 20개 연구 → 유의한 개선 (MD -2.16, 95% CI -3.44~-0.88, p<0.001).
• TCM 증후 점수: 35개 연구 → 유의한 감소 (MD -3.96, 95% CI -5.41~-2.51, p<0.00001).
• TCM 유효율: 62개 연구 → 증가 (RR 0.89, 95% CI 0.80~0.93, p<0.00001).
• 6분 보행거리(6MWD): 25개 연구 → 평균 37.81m 증가 (MD 37.81, 95% CI 20.90~54.73, p<0.001, I²=14.6%). 이는 운동 내성 향상을 시사하며, COPD 예후 지표로 중요한 의미.
• 삶의 질(QoL): 17개 연구 → 유의한 개선 없음 (SMD -0.01, p=0.859).
• 안전성: 심각한 부작용 없음 (경미한 소화불량 등 보고 적음).

토론 및 결론

중등도~저등급 증거로, 안정기 COPD에서 TCM(주로 CHM)을 CT에 보조적으로 사용하면 폐기능, 증상(CAT), 운동 능력(6MWD), TCM 증후가 개선되며 안전하다. 급성 악화 감소는 경향성만 보임. 강점: 이중맹검 RCT만 포함, 통합 TCM 접근. 한계: 연구 대부분 중국산(편향 가능), 샘플 크기 작음, 위험 편향 불명확(배정 은폐, 맹검 등), 다양한 처방으로 이질성, 출판 편향 의심. 대규모 고품질 RCT 필요. 임상적으로 TCM 보조 사용 고려 가능하나, 증거 한계 인지해야 함.

이 논문은 COPD에서 한약(중의학) 보조 요법의 잠재적 이점을 보여주며, 특히 6MWD 38m 가까이 증가는 폐재활과 유사한 수준의 임상적 의미를 가짐 (MCID 기준 25~35m).

• 대상: 294명의 COPD 환자 (주로 중등도~중증).
• 추적 기간: 기준선(baseline)에서 시작해 매년 5년 동안 6MWD 측정 (ATS 가이드라인에 따라 2회 검사 후 최고값 채택).
• 동시에 **FEV1(1초 강제호기량)**도 매년 측정하여 비교.
• 환자들의 연령, 성별, GOLD 단계 등 분포 고려.

• 기준선 6MWD: 중앙값 380m (범위 160~600m).
• 연간 감소율: 평균적으로 6MWD는 매년 감소하며, 특히 중증 COPD(GOLD 단계 높을수록)에서 감소가 더 컸다.
• 6MWD의 변화는 FEV1 감소와 상관관계가 있었으나, 중증 환자에서 운동 능력(6MWD) 손실이 폐기능(FEV1) 손실보다 더 빠르게 진행되는 것으로 나타남.
• 생존 예측: 낮은 기준 6MWD(특정 cut-off 이하)는 사망 위험 증가와 관련. 지속적인 6MWD 감소는 예후 악화 예측에 유용.

• COPD 환자에서 6MWD는 시간 경과에 따라 점진적으로 감소하며, 이는 질병 진행을 반영한다.
• 특히 중증 COPD에서 6MWD가 FEV1보다 더 민감하게 기능 저하를 나타내어, 예후 예측 지표로 FEV1을 보완할 수 있다.
• 이 연구는 6MWD를 COPD의 다차원 평가(예: BODE 지수)에 포함시키는 근거를 강화하며, 장기 모니터링에서 유용함을 시사한다.

COPD(만성 폐쇄성 폐질환) 환자에서
**6분 보행거리(6-minute walk distance, 6MWD)**는
운동 능력, 예후 예측(사망률, 입원 위험),
치료 효과 평가에 중요한 지표로 사용됩니다.

주요 연구(RCT, 메타분석 중심) 결과를 요약하면 다음과 같습니다.

1. 예후 예측 관련

• 대규모 코호트 연구(14,497명 COPD 환자, 관찰 및 개입 연구 포함): 6MWD가 사망, 입원, 급성 악화 예측에 유용하며, 임상 시험에서 환자 층화(stratification) 도구로 활용 가능. 지역/연구 유형에 따른 변동성에도 불구하고 일관된 예측력 확인.
• ECLIPSE 연구(2,110명 GOLD II-IV COPD): 기준 6MWD <334m는 사망 위험 증가, <357m는 악화 입원 위험 증가 예측.
• 6MWD 30m 이상 감소 시 사망 위험 증가(1년 추적 관찰).

2. 최소 임상적 중요 차이(MCID)

• 중증 COPD 환자에서 MCID는 25~35m로 제안(예: 26±2m 또는 25m). 30m 변화는 개별 환자 수준에서 더 의미 있음.
• 폐재활 후 6MWD 변화와 삶의 질 변화는 상관관계 낮음.

3. 폐재활(pulmonary rehabilitation) 효과

• 폐재활 후 6MWD 평균 30~70m 증가 보고(예: 입원 폐재활에서 중증 COPD 환자 생존율 향상과 관련).
• 지역 기반 유지 프로그램 RCT: 50% 이상 참여 시 1년 후 69m 증가.
• Baduanjin(팔단금) 운동 RCT(2024): 안정기 COPD에서 6MWD 및 증상 개선(기존 재활과 유사 효과).

4. 한의학/중의학 치료 관련 (이전 문맥 연계)

• Bufei Yishen formula 등 중의약 병용 메타분석: 6MWD 평균 37~65m 증가, 급성 악화 감소.
• Yihuo Huatan formula RCT: 6MWD 개선 및 염증 억제 확인.

6MWD는 학습 효과(첫 번째 vs 두 번째 검사에서 20~40m 증가)가 있어
baseline 평가 시 2회 검사 권장.

중증 COPD에서 특히 예후 지표로 강력하며, 폐재활이나 보조 요법(한약 포함)으로 개선 가능.

COPD(만성 폐쇄성 폐질환) 환자에서 한약재의 효과를 평가한 주요 RCT 및 메타분석 결과를 요약하면, 대부분 서양의학(흡입제 등) 병용 시 증상 완화, 삶의 질 개선, 급성 악화 감소, 폐기능 향상 등의 효과가 관찰되었습니다. 증거 수준은 중등도(편향 위험 있음)로, 대규모 고품질 연구가 더 필요합니다. 안전성은 대체로 양호하나, 장기 사용 시 모니터링 권장.

주요 한약 처방 및 RCT 요약

1. Bufei Granule / Bufei Yishen Granule (보폐과립 / 보폐익신과립)
   • 구성: 인삼, 황기 등 폐기 보강, 기허 보충 중심.
   • RCT 및 메타분석: 안정기 COPD 환자에서 폐기능(FEV1, FVC) 개선(SMD 0.43~0.70), 삶의 질(SGRQ 점수) 향상, 급성 악화 빈도 감소. 중증(GOLD 3-4) 환자에서 급성 악화 및 입원 감소 확인. 병용 시 효과 우수.
   • 증거: 다수 RCT(599명 이상) 및 메타분석에서 유의미한 개선.

COPD(만성 폐쇄성 폐질환)의 주요 병인 중 하나인 **기도 상피세포 노화(cellular senescence)**를 **Bufei Yishen formula (BYF, 보폐익신방)**가 억제하는지, 그리고 그 기전(특히 AMPK-Sirt1-FoxO3a 경로 활성화와 자가포식(autophagy) 촉진)을 규명하는 것. BYF는 COPD 임상에서 증상 개선 효과가 알려져 있으나, 세포 노화 억제 기전은 불분명했다.
방법

• 동물 모델: 수컷 Sprague-Dawley 쥐 48마리. COPD 모델은 흡연(하루 2회) + Klebsiella pneumoniae 감염(5일마다)으로 8주간 유발. 9~16주간 BYF 고용량(11.6 g/kg), 저용량(5.8 g/kg), 또는 N-acetylcysteine(NAC) 투여.
• 세포 모델: 인간 기관지 상피세포(16HBE)에 cigarette smoke extract(CSE) 10% + LPS 100 ng/mL로 노화 유발. BYF 추출 분획(BYF4/5) 또는 주요 성분(hesperidin, nobiletin) 전처리.
• 분석: 폐기능(전신 폐용적 측정), 조직병리(H&E 염색), 노화 마커(p21, p53, γH2AX, SA-β-gal 등), 염증/산화 스트레스 지표, 상피 장벽 단백질, 자가포식 마커(면역형광, Western blot, qPCR 등). 네트워크 약리학(67개 화합물 동정, 770개 타겟 예측) 및 전사체 분석(RNA-seq) 병행.

주요 결과

• 동물 모델: BYF 투여군에서 폐기능(조용호기량, 분당 환기량, 최대 호기 유량 등) 유의한 개선(p < 0.05~0.01), 병리적 손상(폐포 직경, 기도 벽 두께) 감소. 노화 마커(p21, γH2AX, TUNEL) ↓, 증식 마커(Ki67) ↑, 염증 사이토카인(IL-1β, IL-6, TNF-α), MMP-2/9 ↓, 상피 장벽 단백질(E-Cadherin 등) ↑ (모두 p < 0.05~0.01).
• 세포 모델: BYF4/5 및 hesperidin/nobiletin이 노화 마커(p21/p53 mRNA/단백질, SA-β-gal 활성) ↓, 염증/분해 효소 mRNA ↓ (p < 0.05~0.01).
• 기전: BYF와 주요 성분이 AMPK-Sirt1-FoxO3a 경로 활성화(p-AMPK ↑, Sirt1 ↑, p-FoxO3a ↓)와 자가포식 촉진(LC3B II ↑, PINK1 ↑)을 통해 노화 억제 (p < 0.05~0.01).
• 네트워크 분석: BYF4/5의 67개 화합물 중 hesperidin과 nobiletin이 핵심; p53, FoxO, AMPK, autophagy 경로 풍부.

논의 및 결론 COPD에서 흡연 등은 기도 상피세포 노화를 유발해 염증(SASP), 산화 스트레스, 기질 분해를 촉진한다. BYF는 AMPK-Sirt1-FoxO3a 축을 활성화하고 자가포식을 촉진해 이러한 노화를 억제하며, 폐기능 및 병리를 개선한다. hesperidin과 nobiletin이 주요 활성 성분으로 확인. 이는 BYF의 COPD 치료 효과를 세포 노화 억제 기전으로 설명하는 최초의 증거.

보폐익신방은 고전 처방이 아닌 현대 한의학 처방으로, 중국 허난중의약대학(Henan University of Chinese Medicine)의 Jiansheng Li(李建生) 교수가 COPD(만성 폐쇄성 폐질환)의 폐신기허(肺腎氣虛) 증후를 타겟으로 개발했습니다. 전통 중의학 이론(補肺益腎, 化痰, 活血)에 기반하며, 다수 임상 및 실험 연구(2012년 이후)에서 COPD 치료 효과가 확인되었습니다. 특허 등록된 처방으로, 원방은 12가지 한약재로 구성되며, 이후 유효성분 호환(ECC-BYF) 버전으로 발전했습니다.
원방 처방 및 용량 (주요 연구 기준, 1첩 기준 생약재 g) 연구마다 약간의 변동이 있으나, 대표적인 구성과 용량은 다음과 같습니다 (대부분 Jiansheng Li 교수팀 연구에서 일관됨):

• 인삼 (人蔘, Renshen): 10~15g (보기익기 주약)
• 황기 (黃芪, Huangqi): 20~30g (보폐익기)
• 숙지황 (熟地黃, Shudihuang) 또는 생지황: 15~20g (익신보혈)
• 산수유 (山茱萸, Shanzhuyu): 10~15g (익신수렴)
• 구기자 (枸杞子, Gouqizi): 10~15g (익신명목)
• 오미자 (五味子, Wuweizi): 6~10g (수렴폐기)
• 진피 (陳皮, Chenpi): 10g (이기화담)
• 반하 (半夏, Banxia) 또는 제베모 (浙貝母, Zhebeimu)**: 10g (화담지해)
• 자소엽 (紫蘇葉, Zisuye) 또는 자소자: 10g (이기강폐)
• 음양곽 (淫羊藿, Yinyanghuo): 10~15g (익신양)
• 적작약 (赤芍, Chishao): 15g (활혈)
• 지룡 (地龍, Dilong): 10g (활혈통락)

총 생약재량은 약 150~200g 정도이며, 과립제나 추출물로 제조 시 1g 추출물 ≈ 3.79g 생약재에 해당합니다. 실제 임상에서는 과립(granule) 형태로 사용되며, 용량은 환자 상태에 따라 조정(예: 고용량 11.6g/kg 동물 실험 환산).
이 처방은 COPD 안정기 치료에 서양의학 병용으로 주로 사용되며, 안전성이 높으나 전문 한의사 처방 하에 사용하세요. 유효성분 버전(ECC-BYF III)은 icariin, astragaloside IV, nobiletin 등 5가지 성분으로 간소화된 형태

1. San-Huang Gu-Ben Zhi-Ke (삼황고본지해 처방)
   • 구성: 황금 등 열청화담 중심.
   • RCT: 안정기 COPD(폐비기허증) 환자에서 증상 완화, 안전성 확인. 이중맹검 위약 대조 연구에서 유효성 평가 중.

1. Yupingfeng Granule (옥평풍과립)
   • 구성: 황기, 백출, 방풍 등 기허 보강.
   • RCT: 안정기 COPD에서 CAT 점수 감소, 삶의 질 향상. 급성 악화 예방 효과.
2. Bufei Jianpi Formula (보폐건피 처방)
   • 구성: 인삼, 황기, 백출 등 폐비 건강.
   • RCT: 점막 면역 개선, 장-폐 축(gut-lung axis) 조절 통해 염증 감소, 폐기능 향상.
3. Panax Ginseng (인삼 단독 또는 처방 내)
   • RCT: 중등도 COPD에서 폐기능(FEV1) 및 운동 능력 개선 보고 있으나, 일부 대규모 RCT(168명)에서 위약 대비 급성 악화 감소나 삶의 질 향상 미미. 염증 억제(NF-κB, MAPK 경로) 기전 확인.

전체 메타분석 요약 (주로 CHM 병용)

• 안정기 COPD: 폐기능(FEV1 MD 0.18L), 6분 보행거리 증가(MD 37m), 급성 악화 감소.
• 증상(CAT, SGRQ) 및 삶의 질 개선, 염증 지표 감소.
• 급성 악화기: 일부 처방(예: Xiaoqinglong Tang)에서 증상 완화.
• 안전성: 부작용 보고 적음, 위약과 유사.

Evid Based Complement Alternat Med

. 2021 Jun 4;2021:5550332. doi: 10.1155/2021/5550332

The Effectiveness of Traditional Chinese Medicine (TCM) as an Adjunct Treatment on Stable COPD Patients: A Systematic Review and Meta-Analysis

K H Chan 1,2,✉, Y Y S Tsoi 3, M McCall 2

• Author information
• Article notes
• Copyright and License information

PMCID: PMC8195656  PMID: 34188688

AbstractBackground

Traditional Chinese medicine (TCM), including Chinese herbal medicine (CHM) and acupuncture, exhibits beneficial effects on stable chronic obstructive pulmonary disease (COPD) such as improving lung function and reducing exacerbation. Previous research studies have examined either CHM or acupuncture alone, which are not the usual practice in TCM clinic setting. We conduct a systematic review for eval‎uating the clinical effectiveness and safety of TCM by combining CHM and acupuncture.

Methods

Databases are searched from inception to November 2019. Randomized controlled trials examining either acupuncture or CHM on stable COPD are included. Primary outcomes include lung functions, exacerbations, and COPD assessment test. Secondary outcomes include quality of life, TCM syndrome score and effective rate, and 6-minute walk distance. Two independent reviewers extract data and assess the quality of evidence and generate meta-analysis and risk of bias by STATA. This protocol follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines.

Results

100 randomized controlled trials (8291 participants) were included to compare add-on Chinese medicine treatment with conventional treatment (CT). Combining CHM with CT improves FEV1 (MD: 0.18, 95% CI: 0.08, 0.28), exacerbation rate (MD: −0.29, 95% CI: −0.61, 0.03), COPD assessment test (MD: −2.16, 95% CI: −3.44, -0.88), TCM syndrome score (MD: −3.96, 95% CI: −5.41, −2.51) and effective rate (RR: 0.89, 95% CI: 0.80, 0.93), and 6-minute walk test (MD: 37.81, 95% CI: 20.90, 54.73). No serious adverse events were reported. Risk of bias: low to unclear.

Conclusions

This review identifies sufficient moderate-to-low-quality evidence to suggest TCM as an adjunct treatment for stable COPD patients. Though heterogeneity was low among studies, the results were limited and the quality of evidence was low or very low based on small sample sizes and risk of bias. Future studies with larger sample sizes are warranted. The trial is registered with CRD42019161324.

1. Introduction

Chronic obstructive pulmonary disease (COPD) is a common, treatable, and preventable disease, which is characterized by chronic respiratory symptoms and airflow limitation owing to airway and/or alveolar abnormalities caused by persistent exposure to noxious gases or molecules. The major known pathogenesis of COPD is a complex mixture of small airway disease, parenchymal destruction, and chronic airway and/or systemic inflammation.

COPD is an important cause of chronic morbidity and mortality in the world, which ranks the fourth in the leading cause of death and is projected to be the third by 2020 [1, 2]. It is a common, preventable, and treatable disease but poses an economic burden on the society. COPD patients are usually characterized by persistent respiratory symptoms and airflow limitation. Occasionally, they may have acute exacerbation induced by respiratory infection and increase the hospitalization and readmission rate.

Current COPD preval‎ence data show significant differences among countries, probably because of different diagnostic criteria, survey techniques, and analytical methods [3]. The Burden of Obstructive Lung Diseases (BOLD) program has reported the preval‎ence and risk factors for COPD in people aged ≥40 in more than 29 countries and found that COPD is more common in men than women [4, 5]. Up to now, there are around three million deaths per year [6]. The preval‎ence of COPD is predicted to rise in the coming 30 years, and by 2030, there might be over 4.5 million deaths per year from COPD and comorbidities [7, 8].

Diagnosis of COPD is primarily by spirometry which measures the patient's airflow limitation. It is the most widely accepted, easily available, and reproducible test of lung function. A ratio of postbronchodilator forced expiratory volume in first second (FEV1)/forced vital capacity (FVC) <0.70 confirm‎s the presence of persistent airflow limitation [9]. Main symptoms include dyspnea, chronic cough, chronic sputum production, wheezing, and chest tightness. But the severity of airflow limitation is weakly correlated with symptoms in clinical context [10], and spirometry itself has a relatively low specificity [11]. So other symptom assessments are required to categorize COPD patients, which commonly include the Modified British Medical Research Council (mMRC) Questionnaire [12] and COPD Assessment Test (CATTM) [13–15].

COPD patients may suffer acute worsening of respiratory symptoms that lead to additional therapy, namely, acute exacerbations [16–19]. There are three classifications of exacerbations: mild (short-acting bronchodilators (SABDs) only), moderate (SABDs plus antibiotics and/or oral corticosteroids), and severe (hospitalization or visiting emergency room). The best indicator of frequent exacerbations (defined as two or more exacerbations per annum) is a history of earlier treated events [20]. Apart from these tests, physical exercise measurements, such as paced shuttle walk test and the unpaced 6-minute walk test, are also suggested for monitoring patient health status and predicting prognosis [21–23].

For stable COPD, the goals of pharmacological therapy are to reduce symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance. Apart from smoking cessation and vaccinations, there are two major classes of medications: bronchodilators and anti-inflammatory drugs. Bronchodilators can increase FEV1 and/or modify other spirometric values and are usually prescribed regularly to prevent or reduce symptoms. Commonly used bronchodilators include short-acting and long-acting beta2-agonists (SABA and LABA, respectively) and short-acting and long-acting anticholinergics (SAMA and LAMA, respectively) [24–27].

Traditional Chinese medicine (TCM) has been using to treat symptoms similar to those in COPD, for instance, cough, sputum, or shortness of breath and has shown beneficial effects for over hundreds of decades. However, there is no such a disease term as COPD in TCM. Instead, COPD patients are classified as having “Fei Zhang” with reference to TCM theory [28]. In a normal TCM clinical setting, either Chinese herbal medicine, acupuncture, or the combination of both is used to relieve COPD symptoms and improve lung functions and/or exercise tolerance [29–32].

TCM is very different from contemporary medicine in both diagnosis and treatment methods. Commonly used TCM treatments include herbal medicinal formula, acupuncture, moxibustion, Tuina, or the combination of them. In a daily TCM healthcare setting, patients with COPD symptoms are often given a set of treatments such as acupuncture/moxibustion, or acupuncture/medicinal formula. Most RCTs for TCM treatments were conducted only on several acupoints, or a single herb or formulae, which is not similar to the usual TCM practice. This study aims to examine the effectiveness and adverse effects of adding TCM treatments on western medicine in stable COPD, to synthesize the best available data towards recommendations of optimal treatment.

The primary objective of this study is to measure the effectiveness of TCM as an adjunct treatment on stable COPD patients in any setting and the adverse events associated with its use in clinical trials measured by lung function and exacerbation rate. The secondary objective of this study is to compare the efficacy of either herbal medicine, acupuncture, or the combination of both on treating stable COPD patients reflected by TCM syndrome score and health status.

•   Population: patients with stable COPD aged >18 years old, of any sex, education, and socioeconomic status

•   Interventions: add-on TCM treatment, either herbal medicine, acupuncture, or the combination of both, on conventional medicine

•   Controls/comparators: mainstream pharmacotherapy for managing stable COPD

•   Outcomes: lung functions as measured by FEV1 using spirometry, exacerbation rate, 6-minute walk test, and health-related quality of life (QoL)

•   Study design: double-blind, randomized controlled clinical trials

2. Methods

This systematic review was prepared with reference to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) [33] and the Cochrane Handbook for Systematic Reviews of Interventions [32] and registered on the international prospective register of systematic review (PROSPERO) on 10.12.2019 (registration number: CRD42019161324). Research protocol and supplementary information are listed in Appendices 1–5.

2.1. Inclusion and Exclusion Criteria for Studies2.1.1. Types of Included Studies

Any randomized controlled trials (RCT) with double-blind assessment of patient-reported outcomes, of which both patients and assessors were blind to the treatments given, were included. RCTs published in a peer-reviewed journal with full text were requested, and unpublished clinical trials with online results available were included.

2.1.2. Types of Excluded Studies

Abstracts alone, nonrandomized trials, case reports, cohort studies, case-control studies, cross-sectional studies, retrospective surveys or chart reviews, editorials, commentaries, and clinical observations were excluded from this systematic review. Other systematic reviews were not included, but the reference lists of similar were searched.

2.1.3. Types of Included Participants

Our search was designed to include (1) patients who were 18 years old or above, regardless of sex, education, race, and socioeconomic status, and (2) patients who were diagnosed with stable COPD according to the diagnostic criteria from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [6]. Stable COPD patients were defined as patients having mild cough, expectoration, and dyspnea.

2.1.4. Types of Excluded Participants

We excluded patients with other diseases such as asthma, tuberculosis, bronchiolitis, congestive heart failure, or other severe complications because we only wanted to examine the efficacy of TCM on stable COPD.

2.1.5. Types of Interventions

We included any herbal drugs, extracted active ingredients, or formula administered orally, which could be either in a form of TCM granules or boiled soup, and compared to no treatment, placebo, or any active comparator plus conventional medicine. We also included any acupuncture treatment, or dry needling, using any acupoint combinations, and compared to no treatment, placebo, or any active comparator plus conventional medicine. Studies in any healthcare and any global setting were included. Interventions either alone or in combination with each other were included.

2.1.6. Types of Outcome Measures

Primary Outcomes. We included the following items as primary outcomes: (1) lung functions by measuring the change in FEV1 [35]; (2) exacerbations defined as time-to-first exacerbation or exacerbation rate [6]; (3) COPD assessment test [36]; and (4) adverse events of any cause.

Secondary Outcomes. As an assessment of COPD patients' quality of life, we included quality of life such as sleep patterns, mood, and mental health and physical exercise regime on a validated scale; (2) TCM syndrome score and effective rate [37]; and (3) 6-minute walk distance [38] as secondary outcomes.

Search Strategy. The lead author (KH) designed the search strategy and carry out the searches. A broad search strategy was used to cover all Chinese herbal medicine and acupuncture RCTs to include as many relevant and potentially included trials as possible, from studies inception to November 2019.

Electronic Searches. The following databases were searched mainly in English and Chinese languages and filtered for humans:

1. PubMed

2. MEDLINE

3. EMBASE

4. Cochrane Central Register of Controlled Trials (CENTRAL)

5. Chinese National Knowledge Infrastructure (CNKI)

6. WANFANG Database

7. Chinese Scientific and Technological Periodical Database (VIP)

8. Chinese Biomedical Database (CBM)

9. Cochrane Library Database

The search strategies were tailor-made to each database with a combination of text words and medical subject headings (MeSH), or an equivalent, and search terms are listed in Table 1.

Table 1.

Search terms used in PubMed.

NumberSearch terms

1	Randomized controlled trial
2	RCT
3	Randomized
4	Randomly
5	Trial
6	Groups
7	Controlled clinical trial
8	1 or 2-7
9	Chronic obstructive pulmonary disease
10	COPD
11	Chronic obstructive airway disease
12	Chronic obstructive respiratory disease
13	Chronic bronchitis
14	Emphysema
15	Chronic airflow obstruction
16	9 or 10-15
17	Chinese Medicine
18	Chinese Herbal Medicine
19	CHM
20	Traditional Chinese Medicine
21	TCM
22	Traditional medicine
23	Herb∗
24	Herb∗medicine
25	Plant medicine
26	Herb formula
27	Herb decoction
28	17 or 18-27
29	Acupuncture
30	Acupoint∗
31	Needling
32	Dry needling
33	29, 30–32
34	8 and 16 and 28 and 33

Open in a new tab

Moreover, the following online registries were searched in English and Chinese language and filtered for humans:

1. ClinicalTrials.gov

2. The metaRegister of controlled trials (mRCT)

3. The World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP)

Searching Other Resources. Bibliographies and reference lists of related publications which match the eligibility criteria were hand searched, such that we did not miss any important references during the selection process.

2.2. Data Collection and Analysis2.2.1. Data Extraction and Management

Two reviewers (KH and YYS) independently extracted study information and outcome data using a standardized data extraction table for RCTs only [39] that includes title, first author, publication year, country, sample size, age and sex of participants, intervention, treatment duration, follow-up period, outcomes, and adverse events. Extracted data were cross-checked and entered into STATA (version 16). Any disagreements about extracted data were adjudicated by the third reviewer (MM) and were resolved by discussion and consensus.

2.2.2. Risk of Bias Assessment

Two authors (KH and YYS) independently assessed the risk of bias for each record using the Cochrane Risk of Bias Tool as reported in the Cochrane Handbook for Systematic Reviews of Interventions [32].

A risk of bias table was included as part of each characteristic of included studies table. When facing disagreements about the risk of bias, a third reviewer (MM) adjudicated and disagreements were resolved by discussion. The risk of bias was assessed at the individual study level and the risk of bias was also considered when assessing Grading of Recommendations, Assessment, Development, and Eval‎uation system (GRADE) [40].

These seven domains were assessed for each included study as outlined by the Cochrane Handbook for Systematic Reviews of Interventions [32]:

1. Random sequence generation (examine potential selection bias): studies were assessed for the methods used to generate the allocation sequence

2. Allocation concealment (examine potential selection bias): studies were assessed for the methods used to conceal allocation to interventions before the study starts

3. Blinding of participants and personnel (examine potential performance bias): studies were assessed for methods used to blind the participants and personnel from knowing which intervention a participant would receive

4. Blinding of outcome assessment (examine potential detection bias): studies were assessed for methods used to blind the outcome assessors from knowing which intervention a participant would receive

5. Incomplete outcome data (examine potential attrition bias): studies were assessed for the nature, number, and handling of incomplete outcome data

6. Selective reporting (examine potential reporting bias): studies were assessed whether all planned outcomes were reported in the results

7. Other bias: studies were assessed for any additional sources of bias as low, unclear, or high and provided rationale

2.2.3. Assessment of Heterogeneity

To eval‎uate clinical heterogeneity, only studies with similar conditions and treatments were compared to get a clinically useful result [32]. Statistical heterogeneity was assessed visually [41] with the I2 statistic and p value. If I2 was larger than 50%, possible reasons were discussed [32].

2.2.4. Data Synthesis

The meta-analysis was conducted on extracted data using STATA (version 16) using a random-effects model. Binary data were expressed as risk ratio with 95% confidence intervals (CIs) and were analyzed by Mantel–Haenszel method. For continuous variables, mean difference (MD) with 95% CIs are calculated. Heterogeneity was examined by I2 tests.

Quality of Evidence. GRADE was used to assess the quality of evidence related to each outcome measure and to provide recommendations for clinical practice [32, 40]. A GRADE rating was assigned for each primary and secondary outcome using the four key levels: high, moderate, low, or very low quality, with reasons provided to upgrade or downgrade [40]. Under certain circumstances, the overall GRADE rating might require adjustment. For instance, a study reported very small sample sizes and results were at risk of being down to play of chance [42]. On the other hand, if no data were reported for an outcome, the term “no evidence” or “lack of evidence” could imply there were data and that the results might show no evidence of effect.

2.2.5. Subgroup Analysis

Subgroup analyses were performed to assess factors such as different TCM dosage, forms, duration of treatment, acupoints used, and measurements of results to see whether they have any impact on the effect estimate. Sensitivity analysis was conducted to examine heterogeneity. The effect of methodological quality, sample size, or missing data was also considered. Analysis was repeated after removing methodologically low-quality studies.

2.2.6. Publication Bias

If more than ten studies were selected, the Egger regression test was used to assess any possible publication bias [43].

2.2.7. Ethical Considerations

There were no ethical issues or approvals needed for this type of study as it used aggregate data already anonymized.

3. Results3.1. Study Identification

The PRISMA study flowchart of search results is shown in Figure 1.

Figure 1.

Open in a new tab

PRISMA study flowchart of search results.

Updated on 1 March 2020, a total of 7124 records are identified from databases and 0 records are found from other sources. After removing duplicates, 6792 titles and abstracts are screened and 323 full-text articles are obtained. Among them, 100 articles are included and 223 are excluded with reasons provided in Appendix 7. No studies are ongoing or under assessment.

3.2. Description of Included Studies

Table 2 summarizes the basic characteristics of 100 included studies. We report sample sizes, ages, course of the disease, and gender for control and intervention groups. Types of Chinese medicine, treatment duration, baseline difference, and quality control are also listed.

Table 2.

Basic characteristics of included studies.

AuthorYearSample size (intervention/control)Age (years) (course of disease (years))Gender (male/female)Intervention#ControlTreatment duration (weeks)Baseline differenceQuality controlControlInterventionControlIntervention

Wang	2019	48/48	63.04 ± 8.39 (12.17 ± 3.51)	62.87 ± 9.35 (12.63 ± 3.84)	25/23	27/21	MSZYQD + CT	CT	12	NSD	NR
Zhu	2019	45/45	63.6 ± 8.4 (13.5 ± 7.4)	61.6 ± 8.5 (13.4 ± 7.3)	23/22	25/20	YQYYTBLMZY + CT	CT	4	NSD	NR
Chen	2019	64/64	67.89 ± 9.58 (3.12 ± 0.45)	66.99 ± 10.77 (3.21 ± 0.36)	31/33	32/32	MXBFD + CT	CT	12	NSD	NR
Zhou	2019	50/50	67.50 ± 6.51 (NR)	63.74 ± 6.5 (NR)	31/19	32/18	BSNQG + CT	CT	8	NSD	NR
Liu	2019	51/52	61.75 ± 8.2 (6.05 ± 2.33)	62.40 ± 0.31 (5.93 ± 2.47)	34/17	36/16	BFHXD + CT	CT	12	NSD	NR
Zhang	2019	30/30	64.02 ± 3.49 (8.02 ± 2.64)	63.82 ± 3.67 (7.85 ± 2.71)	16/14	17/13	MSZJQD + CT	CT	8	NSD	NR
Zhang	2019	72/72	45.18 ± 6.30 (7.25 ± 1.99)	45.30 ± 6.12 (7.38 ± 1.99)	41/31	45/27	SMZYYFD + CT	CT	12	NSD	NR
Lin	2019	33/33	68.24 ± 9.76 (22.30 ± 2.75)	70.62 ± 9.38 (23.52 ± 2.89)	20/13	21/12	YSBFG + CT	CT	24	NSD	NR
Wang	2019	73/73	62.05 ± 5.13 (6.40 ± 1.25)	63.32 ± 4.59 (6.02 ± 1.14)	47/16	44/29	SMQFWSHTD + CT	CT	12	NSD	NR
Jin	2019	30/30	NR	NR	NR	NR	SLBZDAAS + CT	CT	12	NSD	NR
Li	2019	40/40	68.25 ± 15.21 (7.82 ± 2.53)	(8.15 ± 2.41)	25/15	23/17	FZHTQYM + CT	CT	12	NSD	NR
Liang	2019	40/40	62 ± 10 (6 ± 5)	64 ± 10 (6 ± 5)	23/17	22/18	GBQFD + CT	CT	12	NSD	NR
Wang	2019	30/30	NR	NR	NR	NR	SLBZDAAS + CT	CT	12	NSD	NR
Chen	2019	38/38	67.52 ± 3.22 (3.03 ± 0.38)	67.56 ± 3.24 (3.05 ± 0.37)	19/19	20/18	SQBFD + CT	CT	8	NSD	NR
He	2019	38/38	62.5 ± 0.5	62.4 ± 0.6	21/17	20/18	SQBFD + CT	CT	8	NSD	NR
Yun	2019	42/42	63.5 ± 11.2 (12.5 ± 4.6)	67.2 ± 14.1 (10.5 ± 5.2)	19/23	22/20	SQGBD + CT	CT	24	NSD	NR
Zeng	2019	30/30	64.43 ± 6.95 (9.5 ± 2.74)	66.20 ± 7.27 (9.0 ± 2.03)	19/11	16/14	LWBQG + CT	CT	32	NSD	NR
Ke	2019	58/58	45.6 ± 7.1 (3.14 ± 0.96)	44.8 ± 6.9 (3.27 ± 0.88)	31/27	35/23	JPYFD + CT	CT	3-4	NSD	NR
Feng	2018	60/60	60.12 ± 2.76 (8.14 ± 2.23)	59.42 ± 2.56 (7.58 ± 1.24)	36/24	38/22	QTJFD + CT	CT	12	NSD	NR
Huang	2018	40/40	65.56 ± 5.83 (5–20)	64.76 ± 6.46 (6–17)	29/11	30/10	JSLJD + THSWD + CT	CT	8	NSD	NR
Xu	2018	30/30	61.4 ± 4.9 (12.3 ± 1.7)	62.6 ± 5.5 (12.6 ± 1.5)	15/15	14/16	BFHXD + CT	CT	28	NSD	NR
Liu	2018	55/55	51.97 ± 17.34 (9.2 ± 5.3)	52.61 ± 16.99 (9.4 ± 4.8)	35/20	34/21	BFHXD + CT	CT	12	NSD	NR
Kang	2018	75/75	61.25 ± 11.57	62.2 ± 12.65	44/31	52/23	BZYQD + CT	CT	24	NSD	NR
Wang	2018	38/38	65.44 ± 6.85 (6.23 ± 2.35)	65.96 ± 6.57 (6.43 ± 2.24)	19/19	20/18	YQBFD + CT	CT	4	NSD	NR
Lu	2018	29/29	58.3 ± 1.3	59.2 ± 1.2	16/13	15/14	LJZD + CT	CT	8	NSD	NR
Yang	2018	30/30	57.14 ± 10.67 (9.92 ± 6.02)	56.75 ± 11.14 (10.36 ± 5.74)	21/9	20/10	FFGSD + CT	CT	12	NSD	NR
Li	2018	40/40	61.2 ± 2.1 (5.4 ± 1.1)	63.4 ± 1.8 (5.1 ± 1.0)	28/12	29/11	MZFWDD + CT	CT	16	NSD	NR
Yang	2018	40/40	75.0 ± 4.5 (5.0 ± 2.2)	74.5 ± 5.0 (5.3 ± 2.1)	28/12	27/13	PKHTD + CT	CT	12	NSD	NR
Gao	2018	80/80	59.7 ± 6.4 (16.4 ± 2.1)	58.8 ± 5.9 (15.9 ± 2.7)	54/26	51/29	SGDHP + CT	CT	8	NSD	NR
Zhang	2018	60/60	62.39 ± 5.43 (13.95 ± 3.79)	64.36 ± 5.65 (13.19 ± 3.99)	37/23	34/26	SGBFD + CT	CT	12	NSD	NR
Wu	2018	15/15	51.46 ± 8.42 (10.01 ± 7.19)	53.25 ± 7.51 (9.85 ± 8.15)	8/7	6/9	SLBZD + CT	CT	12	NSD	NR
Lu	2018	40/40	64.49 ± 8.22 (7.82 ± 0.92)	65.28 ± 8.31 (7.79 ± 0.90)	25/15	26/14	SQBFD + CT	CT	4	NSD	NR
Feng	2018	42/42	63.1 ± 8.7 (NR)	64.7 ± 9.2 (NR)	24/18	25/17	SQBFD + CT	CT	12	NSD	NR
Yue	2018	43/42	528.±4.9 (12.3 ± 3.7)	53.6 ± 3.2 (11.4 ± 2.2)	25/18	23/19	SQBFD + CT	CT	12	NSD	NR
Xu	2018	60/60	65.65 ± 1.36 (10 ± 0.27)	66.35 ± 2.16 (10 ± 0.65)	38/22	36/24	MBXXXD + CT	CT	8	NSD	NR
Tu	2018	30/30	60.00 ± 6.80 (11.53 ± 4.90)	62.60 ± 5.74 (11.92 ± 5.02)	29/1	28/2	MLJZD + CT	CT	12	NSD	NR
Li	2018	44/44	69.58 ± 1.02 (12.1 ± 3.4)	69.42 ± 1.03 (13.2 ± 4.5)	26/18	28/16	YFBJD + CT	CT	4	NSD	NR
Dai	2017	36/36	64 ± 7.2 (18.64 ± 10.61)	63.33 ± 6.11 (15.61 ± 8.05)	19/17	18/18	SSSQD + CT	CT	12	NSD	NR
Zhou	2017	30/30	72.05 ± 7.62(6.03 ± 1.09)	71.89 ± 7.56(6.57 ± 1.14)	17/12	18/12	MZFWDF + CT	CT	12	NSD	NR
Liu	2017	40/40	64.21 ± 6.91(13.56 ± 8.62)	66.17 ± 6.02(12.89 ± 7.94)	27/13	25/15	ZYZYF + CT	CT	4.29	NSD	NR
Yu	2017	42/41	63.34 ± 5.19 (NR)	63.34 ± 5.19 (NR)	20/21	21/21	BZYQD + CT	CT	24	NSD	NR
Zhang	2017	50/50	52.02 ± 3.10(12.80 ± 2.11)	53.23 ± 3.02(13.30 ± 2.01)	27/23	28/22	SZYQD + CT	CT	2	NSD	NR
Kong	2017	30/30	56.5 ± 13.5(9.5 ± 5.5)	55 ± 13(9 ± 6)	19/11	17/13	BFFCD + CT	CT	12	NSD	NR
Wang	2017	30/30	69.43 ± 4.897(5.80 ± 2.709)	68.00 ± 6.119(6.10 ± 2.746)	18/12	21/9	ILANKM + CT	CT	8.57	NSD	NR
Wang	2017	42/41	66.43 ± 7.76(5.73 ± 1.64)	67.08 ± 7.43(6.02 ± 1.58)	24/17	26/17	BFHXD + CT	CT	24	NSD	NR
Zhao	2017	42/42	61.32 ± 10.03 (NR)	62.99 ± 9.10 (NR)	24/18	23/19	BFD + CT	CT	8	NSD	NR
Gong	2017	45/44	59.62 ± 5.97(19.61 ± 4.85)	59.63 ± 5.96(19.62 ± 5.97)	24/20	24/21	BFJPYSD + CT	CT	4	NSD	NR
Dong	2017	33/32	66.3 ± 8.3 (NR)	66.5 ± 8.1 (NR)	15/17	16/17	GJDCP + CT	CT	12	NSD	NR
Zhou	2017	35/35	53.7 ± 10.9 (NR)	53.7 ± 10.9 (NR)	34/36	34/36	SMYFPCD + CT	CT	12	NSD	NR
Xiao	2017	25/25	64.3 ± 5.7(8.5 ± 2.3)	64.5 ± 5.3(8.3 ± 2.1)	18/7	16/9	SMWBPSD + CT	CT	12	NSD	NR
Li	2017	50/50	70.06 ± 3.09(6.12 ± 1.12)	70.61 ± 3.11(6.02 ± 1.05)	26/24	27/23	SMYYQFD + CT	CT	1	NSD	NR
Wen	2017	33/34	56.85 ± 5.47(8.36 ± 3.63)	56.85 ± 5.47(8.36 ± 3.63)	NR	NR	FLK + CT	CT	12	NSD	NR
You	2017	83/83	63.75 ± 5.91(7.08 ± 1.51)	63.37 ± 5.87(6.88 ± 1.53)	46/37	50/33	YQHTQYTLD + CT	CT	8.57	NSD	NR
Lu	2017	38/38	64.20 ± 13.40 (NR)	64.20 ± 13.40 (NR)	22/16	19/19	WBFSM + CT	CT	24	NSD	NR
Yang	2017	40/40	NR	NR	34/6	31/9	FFGSD + CT	CT	12	NSD	NR
Lu	2017	44/44	NR	NR	NR	NR	PCGBD + CT	CT	24	NSD	NR
Lu	2017	31/31	63.5 ± 4.1(4.2 ± 0.8)	64.2 ± 4.2(4.0 ± 0.6)	17/14	18/13	SLBZPAAS + CT	CT	12	NSD	NR
Li	2017	38/38	40.32 ± 3.12 (NR)	40.65 ± 3.08 (NR)	21/17	22/16	MSGP + CT	CT	8	NSD	NR
Guo	2017	46/46	59.1 ± 5.9 (NR)	58.±5.7 (NR)	27/19	29/17	YYQFD + CT	CT	4	NSD	NR
Zhao	2017	50/50	67.45 ± 3.14(4.8 ± 1.1)	65.32 ± 2.25(4.7 ± 1.2)	34/16	38/12	SMLRD + CT	CT	2	NSD	NR
Lin	2017	34/34	60.49 ± 8.26(7.01 ± 2.39)	60.49 ± 8.26(6.89 ± 2.60)	19/15	19/15	MLJZD + CT	CT	12	NSD	NR
Lou	2016	60/59	71.2 ± 5.7(19.23 ± 4.53)	72.35 ± 4.77(18.42 ± 3.37)	36/23	35/35	JQNSM + CT	CT	12	NSD	NR
Ye	2016	42/42	63.14 ± 12.08(6.84 ± 2.99)	62.47 ± 11.08(7.01 ± 3.68)	24/18	22/20	TBFSM + CT	CT	12	NSD	NR
Bian	2016	25/25	60.3 ± 5.7(16.4 ± 3.6)	60.3 ± 5.7(16.4 ± 3.6)	NR	NR	BSFCD + CT	CT	12	NSD	NR
Li	2016	30/30	61.33 ± 11.50(14.12 ± 5.3)	62.2 ± 12.67(12.5 ± 4.88)	16/14	19,11	ZLFSQXDGFTJ + CT	CT	8	NSD	NR
Tang	2016	34/34	65.87 ± 9.08 (NR)	63.77 ± 8.64 (NR)	20/14	23/11	ZCG + CT	CT	8	NSD	NR
Guo	2016	49/49	69.3 ± 2.5(5.4 ± 0.7)	70.2 ± 2.3(5.6 ± 0.5)	28/21	27/22	MZFWDF + CT	CT	12	NSD	NR
Fang	2016	59/59	64.02 ± 11.15(6.79 ± 2.14)	63.87 ± 10.62(6.32 ± 2.02)	36/23	35/24	SLBZPAAS + CT	CT	12	NSD	NR
Chen	2016	30/30	66.1 ± 5.8(6.3 ± 1.6)	65.6 ± 5.1(6.5 ± 1.8)	17/13	19/11	LJF + CT	CT	8	NSD	NR
Hu	2016	30/30	67.90 ± 7.34(16.47 ± 6.95)	68.63 ± 6.49(14.87 ± 9.07)	19/11	18/12	BFDAAS + CT	CT	8	NSD	NR
Liang	2015	42/42	63.14 ± 12.08(6.84 ± 2.99)	62.47 ± 11.08(7.01 ± 3.68)	24/18	22/20	TBFSM + CT	CT	12	NSD	NR
Wang	2015	37/37	67.13 ± 6.95(3.92 ± 0.39)	66.72 ± 7.92(3.85 ± 0.44)	15/22	18/19	BFYSD + CT	CT	1	NSD	NR
Si	2015	40/40	70.43 ± 8.73(16.30 ± 5.19)	72.04 ± 9.36(18.30 ± 5.84)	22/18	25/15	BFJPYSD + CT	CT	NR	NSD	NR
Wang	2015	36/36	60.51 ± 11.03(14.52 ± 5.96)	60.81 ± 8.18(14.56 ± 6.32)	22/14	21/15	BZGWHJ + CT	CT	8	NSD	NR
Li	2015	38/38	57.18 ± 9.92 (NR)	56.63 ± 10.23 (NR)	23/15	20/18	YQBSHXF + CT	CT	12	NSD	NR
He	2015	25/25	NR	NR	NR	NR	SLBZG + CT	CT	36	NSD	NR
Huang	2015	40/41	67.28 ± 4.30(8.9 ± 7.8)	65.36 ± 2.10(8.8 ± 7.1)	25/16	23/17	KFZY + CT	CT	36	NSD	NR
Zhang	2015	45/30	63.2 ± 11.5 (NR)	63.8 ± 10.7 (NR)	18/22	29/16	SXDAAS + CT	CT	12	NSD	NR
Luo	2014	80/80	66.8 (15.49)	64.8 (16.32)	62/18	64/16	BFPCD + CT	CT	12	NSD	NR
Wen	2014	40/40	68.3 ± 9.0(15.4 ± 3.6)	68.6 ± 9.2(15.7 ± 3.8)	28/12	30/10	BFDAAS + CT	CT	8	NSD	NR
Li	2014	49/49	61.37 ± 4.18(10.6 ± 8.9)	63.52 ± 3.67(11.4 ± 7.3)	30/19	32/17	BFNSF + CT	CT	3	NSD	NR
Qi	2014	80/80	55.9 ± 3.9(8.2 ± 3.1)	56.3 ± 4.2(7.9 ± 4.2)	46/34	44/36	WSBFHTT + CT	CT	8	NSD	NR
Zeng	2014	43/42	66.9 ± 7.9(14.8 ± 3.9)	67.4 ± 7.2(15.3 ± 4.5)	29/13	28/15	MSZYQD + GZLMD + CT	CT	12	NSD	NR
Zhang	2014	30/30	40.46 ± 16. (NR)	45.35 ± 15.32 (NR)	12/18	7/23	QZYQDG + CT	CT	2	NSD	NR
Chen	2013	30/30	63.51 ± 11.24(10.86 ± 7.54)	62.54 ± 12.56(11.61 ± 8.44)	18/12	16/14	BFYSQTD + CT	CT	42	NSD	NR
Tan	2013	45/34	NR	NR	NR	NR	BZYQM + CT	CT	2.14	NSD	NR
Zhang	2013	33/33	63.57 ± 11.47(33.57 ± 10.97)	62.03 ± 10.94(33.26 ± 9.41)	19/14	20/13	QYJDF + CT	CT	4	NSD	NR
Liang	2013	40/40	NR	NR	38/2	33/7	RFJPBSD + CT	CT	12	NSD	NR
Jiang	2013	30/30	61.7 ± 3.2 (NR)	64.0 ± 2.1 (NR)	19/11	17/13	SLBZG + CT	CT	24	NSD	NR
Wang	2013	30/30	NR	NR	NR	NR	SLBZDAAS + CT	CT	12	NSD	NR
Dai	2013	40/40	NR	NR	NR	NR	SMBPYQD + CT	CT	12	NSD	NR
Chen	2012	30/30	60.81 ± 8.57 (NR)	65.63 ± 7.43 (NR)	21/9	23/7	GBQTHYD + CT	CT	24	NSD	NR
Chen	2011	50/50	67.73 ± 6.11(9.75 ± 3.56)	69.51 ± 5.41(9.45 ± 4.12)	41/9	38/12	FGFZM + CT	CT	12	NSD	NR
Gong	2011	30/30	68.4 ± 6.2 (NR)	67.4 ± 6.8 (NR)	19/11	17/13	SETGM + CT	CT	24	NSD	NR
Tang	2010	34/35	71.00 ± 10.53(15.46 ± 10.89)	72.18 ± 10.78(14.53 ± 9.15)	26/9	23/11	JPYSD + CT	CT	12	NSD	NR
He	2010	49/49	NR	NR	NR	NR	SETGM + CT	CT	24	NSD	NR
Wang	2009	36/28	61.5 ± 4.8(15.6 ± 4.7)	62.1 ± 5.3(16.3 ± 5.1)	21/7	25/11	SMBFTFD + CT	CT	24	NSD	NR
Wang	2008	32/26	61.5 ± 4.8(15.6 ± 4.7)	62.1 ± 5.3(16.3 ± 5.1)	20/6	23/9	BFTFD + CT	CT	NR	NSD	NR
Jiang	2008	30/25	63.2 ± 5.3(13.12 ± 3.38)	61.6 ± 6.1(15.25 ± 4.01)	17/8	23/7	SMYQHXD + CT	CT	24	NSD	NR
Hong	2018	30/30	68.59 ± 7.72 (15.70 ± 5.59)	67.93 ± 7.78 (14.57 ± 5.50)	27/1	28/0	YFN + CT	CT	8	NSD	YES

Open in a new tab

NSD = not significantly different; NR = not reported; CT = conventional treatment. # Detailed description of CHM in Appendix 6.

3.2.1. Design

All studies are randomized, double-blind, and controlled clinical trials and report primary and secondary outcomes.

3.2.2. Sample Size

Sample sizes range from 15 participants per arm [44] to 83 participants per arm [45]. Ages range from 40.32 ± 3.12 (mean ± SE) [46] to 71.2 ± 5.7 [47] in the control group and from 40.65 ± 3.08 [46] to 72.35 ± 4.77 [47] in the intervention group. Ten studies do not report the mean age [48–57].

3.2.3. Participants

All studies recruit participants according to the GOLD guidelines [6], and all participants are in stable phase with stages between II and IV. The course of disease (in years) ranges from 3.03 ± 0.38 (mean ± SE) [58] to 33.57 ± 10.97 in the control group [28] and from 3.05 ± 0.37 [58] to 33.26 ± 9.41 [28] in the intervention group. Thirty studies do not report the course of years shown in Table 2.

3.2.4. Setting and Location

All studies are single-centered trials and based in hospital settings. The location of studies scatters across different provinces in China.

3.2.5. Interventions

Comparison Arms. There is no acupuncture plus conventional medicine versus conventional treatment (CT) identified. Ninety-nine studies compare one Chinese herbal medicine (CHM) formulae plus CT with conventional medicine. One study has three arms: conventional medicine, CHM decoction plus CT, and CHM powder plus CT [48].

Types of Chinese Medicine. One hundred different CHM formulae are used and detailed compositions and dosages of each formula are shown in Appendix 6. Conventional medicine is prescribed with reference to GOLD guidelines.

Duration of Treatment. The duration of treatment differs across studies, which ranges from 1 week [59] to 42 weeks [60]. The mean duration of treatment is 14 weeks. Two studies do not report the duration of treatment [61, 62].

3.2.6. Outcomes

Table 3 summarizes the availability of outcome measures reported. Forty studies report a change in FEV1 (mean ± SE). Thirteen studies report exacerbation rate (mean ± SE) as a continuous outcome at the study endpoint. Twenty studies report COPD assessment test (mean ± SE). Twenty-five studies report 6-minute walk test (mean ± SE). Thirty-five studies report TCM syndrome score (mean ± SE) and sixty-two studies report TCM effective rate as dichotomous outcome. For quality of life, seventeen studies report in different QoL scales (mean ± SE), including SGRQ and COPD quality of life. Only one study reports all withdrawals [63]. Eight studies report adverse events of any cause with reason provided. One study reports withdrawals due to lack of efficacy [56]. Thirteen studies report none of the primary and secondary outcomes.

Table 3.

Availability of outcome indexes.

AuthorYearAvailable outcome index

Wang	2019	TCM syndrome score, TCM effective rate, FEV1, 6MWT
Zhu	2019	Nil
Chen	2019	FEV1
Zhou	2019	TCM effective rate, CAT, QoL, exacerbation rate
Liu	2019	TCM syndrome score, TCM effective rate, FEV1, 6MWT, QoL, adverse events
Zhang	2019	TCM syndrome score, FEV1, CAT, TCM effective rate
Zhang	2019	TCM syndrome score, FEV1, 6MWT, exacerbation rate, TCM effective rate
Lin	2019	TCM syndrome score, CAT, TCM effective rate
Wang	2019	TCM syndrome score, FEV1, 6MWT, TCM effective rate, adverse events
Jin	2019	Nil
Li	2019	TCM syndrome score, FEV1, 6MWT
Liang	2019	TCM syndrome score, CAT
Wang	2019	Nil
Chen	2019	FEV1
He	2019	TCM syndrome score, FEV1
Yun	2019	TCM syndrome score, TCM effective rate, FEV1, CAT
Zeng	2019	TCM effective rate, exacerbation rate, CAT
Ke	2019	FEV1, QoL
Feng	2018	TCM syndrome score, TCM effective rate, FEV1, 6MWT, QoL
Huang	2018	TCM effective rate, FEV1, CAT, 6MWT
Xu	2018	TCM syndrome score, TCM effective rate, FEV1, QoL
Liu	2018	TCM syndrome score, FEV1
Kang	2018	TCM syndrome score
Wang	2018	TCM effective rate, QoL, FEV1
Lu	2018	TCM effective rate, FEV1
Yang	2018	TCM effective rate, FEV1, CAT, 6MWT, exacerbation rate
Li	2018	TCM effective rate, exacerbation rate, 6MWT, QoL
Yang	2018	TCM effective rate, FEV1
Gao	2018	TCM effective rate
Zhang	2018	TCM effective rate, TCM syndrome score, CAT, FEV1
Wu	2018	TCM syndrome score, 6MWT, CAT
Lu	2018	TCM syndrome score
Feng	2018	TCM effective rate
Yue	2018	TCM effective rate
Xu	2018	TCM effective rate, FEV1
Tu	2018	CAT
Li	2018	TCM effective rate
Dai	2017	FEV1, CAT
Zhou	2017	TCM effective rate, exacerbation rate
Liu	2017	6MWT, adverse events
Yu	2017	TCM effective rate, QoL, 6MWT
Zhang	2017	FEV1, CAT, TCM effective rate
Kong	2017	FEV1
Wang	2017	TCM syndrome score, TCM effective rate, 6MWT, CAT
Wang	2017	FEV1, 6MWT
Zhao	2017	TCM syndrome score
Gong	2017	FEV1, TCM effective rate
Dong	2017	TCM syndrome score, TCM effective rate
Zjou	2017	TCM effective rate
Xiao	2017	FEV1, QoL, 6MWT
Li	2017	TCM effective rate, FEV1, adverse events
Wen	2017	TCM effective rate, FEV1
You	2017	TCM effective rate, adverse events
Lu	2017	Nil
Yang	2017	Nil
Lu	2017	TCM syndrome score, TCM effective rate
Lu	2017	TCM effective rate
Li	2017	Nil
Guo	2017	FEV1, TCM effective rate
Zhao	2017	TCM effective rate
Lin	2017	TCM effective rate, TCM syndrome score, CAT
Lou	2016	TCM syndrome score, 6MWT, exacerbation rate
Ye	2016	TCM syndrome score, QoL, TCM effective rate, FEV1, 6MWT, exacerbation rate
Bian	2016	Nil
Li	2016	6MWT
Tang	2016	QoL, TCM effective rate
Guo	2016	TCM effective rate
Fang	2016	TCM effective rate, 6MWT
Chen	2016	TCM effective rate
Hu	2016	TCM effective rate, 6MWT, CAT
Liang	2015	TCM syndrome score, TCM effective rate, 6MWT, QoL, FEV1, exacerbation rate
Wang	2015	TCM effective rate, FEV1
Si	2015	QoL
Wang	2015	CAT
Li	2015	Nil
He	2015	TCM effective rate, FEV1, QoL
Huang	2015	FEV1, 6MWT, adverse events
Zhang	2015	CAT, 6MWT, TCM effective rate, exacerbation rate, adverse events
Luo	2014	6MWT, exacerbation rate, TCM effective rate, adverse events
Wen	2014	TCM effective rate
Li	2014	FEV1, TCM effective rate
Qi	2014	TCM effective rate, TCM syndrome score
Zeng	2014	Nil
Zhang	2014	TCM effective rate, TCM syndrome score
Chen	2013	TCM syndrome score
Tan	2013	FEV1, TCM effective rate
Zhang	2013	TCM effective rate, TCM syndrome score, FEV1
Liang	2013	TCM syndrome score, 6MWT
Jiang	2013	CAT, TCM syndrome score, FEV1
Wang	2013	TCM effective rate
Dai	2013	Nil
Chen	2012	TCM effective rate, TCM syndrome score
Chen	2011	TCM effective rate, FEV1, TCM syndrome score, exacerbation rate
Gong	2011	FEV1, TCM effective rate, QoL
Tang	2010	TCM syndrome score, TCM effective rate, QoL
He	2010	TCM syndrome score, exacerbation rate
Wang	2009	Nil
Wang	2008	Nil
Jiang	2008	Nil
Hong	2018	TCM effective rate, CAT, 6MWT, adverse events, all withdrawals

Open in a new tab

FEV1 = forced expiratory volume in 1 s; CAT = COPD assessment test; 6MWT = 6-minute walk test; QoL = quality of life.

3.2.7. Language

One full text is written in English. The remaining 99 full texts are written in Chinese and are translated by KH (myself).

3.3. Description of Excluded Studies

Two hundred and twenty-three studies are excluded after reading the full-text articles. Detailed exclusion reasons for each study are shown in Appendix 7.

Sixty-four studies (29%) are excluded because the participants are not stable COPD patients, or there is no evidence to indicate the disease phase.

Ninety-seven studies (43%) are excluded due to interventions. Reasons include that (1) CHM is not administered in the form of decoction or granules, (2) intervention group does not combine with conventional treatment, (3) intervention is not CHM or acupuncture, and (4) there is more than one CHM treatment.

Nine studies (4%) are excluded in the absence of control group or conventional treatment. Twelve studies (6%) do not report the wanted primary and secondary outcomes or do not use “intention-to-treat” analysis.

Forty-one studies (18%) are not included in the light of study designs, with reasons being not randomized or no such evidence.

3.4. Risk of Bias Summary of Included Studies

The risk of bias summary diagram shows the risk of bias for all included studies from low to unclear (Table 4). No study shows a low risk of bias in all six domains. Two studies (2%) show a high risk of bias in one domain [51, 56]. Ninety-nine studies (99%) display unclear risk of bias in four domains and one study (1%) shows unclear risk in two domains [63].

Table 4.

Risk of bias assessments of included studies.

Open in a new tab

3.4.1. Random Sequence Generation (Selection Bias)

All studies describe their randomization methods which are mostly random number generation by 1 : 1 ratio (low risk).

3.4.2. Allocation Concealment (Selection Bias)

All studies do not report information about the concealment method of what types of treatment are given to participants (unclear risk).

3.4.3. Blinding of Participants and Personnel (Performance Bias)

Ninety-nine studies (99%) provide no information on how participants and research personnel are blinded (unclear risk). One study reports adequately the blinding procedures of both participants and personnel (low risk) [63].

3.4.4. Blinding of Outcome Assessors (Detection Bias)

Ninety-nine studies (99%) provide no information how participants and research personnel are blinded (unclear risk). One study reports adequately the blinding procedures of both participants and personnel (low risk) [63].

3.4.5. Incomplete Outcome Data (Attrition Bias)

Ninety-nine studies (99%) do not report dropouts and withdrawals (unclear risk). One study (1%) reports withdrawal numbers but no reasons provided (unclear risk) [63].

3.4.6. Selective Reporting (Reporting Bias)

Ninety-eight (98%) studies report all outcomes as prespecified in their protocol and two studies (2%) miss some outcome data (high risk) [51, 56].

3.5. Outcome Measures

One hundred studies are included with a total of 8,318. Forty studies report change in FEV1. Thirteen studies report exacerbation rate at the study endpoint. Twenty studies report COPD assessment test. Twenty-five studies report 6-minute walk test. Thirty-five studies report TCM syndrome score and sixty-two studies report TCM effective rate as dichotomous outcome. Seventeen studies report various QoL scales. Eleven studies report all withdrawals. Eight studies report adverse events of any cause with reason provided. One study reports withdrawals due to lack of efficacy. Thirteen studies report none of the primary and secondary outcomes.

3.5.1. Primary Outcome: Change in FEV1

Forty studies report the mean and standard error (SE) of FEV1 (in liters) at baseline and endpoint of the study. Data are converted to standard deviation (SD) and meta-analyzed in Figure 2. The results are presented as mean change in FEV1 and SD. The effect estimate is 0.18 (95% CI: 0.08, 0.28; p ≤ 0.001) with I2 = 0.0% (p=1.000), which means intervention significantly increases FEV1 by 0.18 liter with zero heterogeneity.

Figure 2.

Open in a new tab

Forest plot of change in FEV1. CI: confidence intervals.

GRADE: the overall quality of this evidence is judged to be moderate, downgraded once for risk of bias and once for imprecision.

3.5.2. Primary Outcome: Exacerbation Rate

Thirteen studies reported the mean exacerbation rate and standard error at the endpoint of the study. Data are converted to standard deviation (SD) and meta-analyzed in Figure 3. The effect estimate was −0.29 (95% CI: −0.61, 0.03; p=0.075733) with I2 = 0.0% (p=0.455).

Figure 3.

Open in a new tab

Forest plot of exacerbation rate. CI: confidence intervals.

GRADE: the overall quality of this evidence is judged to be very low, downgraded once for risk of bias, once for imprecision, and once for too few data from included studies.

3.5.3. Primary Outcome: COPD Assessment Test

Twenty studies report COPD assessment test (CAT) with mean and standard error. Data are converted to standard deviation (SD) and meta-analyzed in Figure 4. The effect estimate is −2.16 (95% CI: −3.44, −0.88; p ≤ 0.001) with I2 = 0.0% (p=0.982). Adding on CHM with conventional medicine significantly reduces the score of CAT.

Figure 4.

Open in a new tab

Forest plot of COPD assessment test. CI: confidence intervals.

GRADE: the overall quality of this evidence is judged to be low, downgraded once for risk of bias and once for imprecision.

3.5.4. Primary Outcome: Adverse Events of Any Cause

Eight studies report adverse events of any cause and data are summarized in Table 5. Of these, four studies have no adverse events throughout the study period [28, 66–68]. Wang reports 2 cases of nausea, Liu reports 1 case of mouth dryness, and Huang reports 3 cases of acute exacerbation with hospitalization. Hong reports 2 epigastric discomfort and 1 diarrhea in the control group and 1 pale yellow phlegm in the intervention group.

Table 5.

Adverse events of any cause.

StudyGroup (number of events)Cause

[56]	Control (0)	—
	Intervention (2)	Nausea
[64]	Control (0)	—
	Intervention (1)	Mouth dryness
[65]	Control (2)	Acute exacerbation
	Intervention (1)	Acute exacerbation
[63]	Control (3)	2 epigastric discomfort, 1 diarrhea
	Intervention (1)	1 pale yellow phlegm

Open in a new tab

GRADE: the overall quality of this evidence is judged to be low, downgraded once for risk of bias and once for imprecision.

3.5.5. Secondary Outcome: Quality of Life

Seventeen studies reported quality of life using different scales. Of these, nine studies used St. George's Respiratory Questionnaire (SGRQ) [69–77]. Eight studies used COPD-Quality of Life (COPD-QoL) questionnaire [54, 67, 78–83].

Standardized mean difference (SMD) and standard deviation (SD) are calculated and meta-analyzed in Figure 5. The summary estimate was −0.01 (95% CI: −0.12, 0.10; p=0.858723) with heterogeneity = 0.0% (p=1.000).

Figure 5.

Open in a new tab

Forest plot of quality of life. CI: confidence intervals; SMD: standardized mean difference.

GRADE: the overall quality of this evidence is judged to be very low, downgraded once for risk of bias, once for inconsistency, and once for imprecision.

3.5.6. Secondary Outcome: TCM Syndrome Score and Effective Rate

Thirty-five studies reported total TCM syndrome score in mean plus standard error and sixty-two studies reported TCM effective rate as a number of events in each group. Data were converted to mean plus standard error and risk ratio. Meta-analysis results are presented in Figures 6 and 7, respectively. The total TCM syndrome score was reduced after adding CHM (effect estimate: MD: −3.96, 95% CI: −5.41, −2.51, p < 0.00001) with I2 = 0.0% (p=0.915). The effect estimate for TCM effective rate was 0.89 (95% CI: 0.86, 0.93, p < 0.00001) with heterogeneity = 0.0% (p=1.000).

Figure 6.

Open in a new tab

Forest plot of TCM syndrome score. CI: confidence intervals.

Figure 7.

Open in a new tab

Forest plot of TCM effective rate. CI: confidence intervals.

GRADE: the overall quality of this evidence is judged to be moderate, downgraded once for risk of bias and once for imprecision.

3.5.7. Secondary Outcome: 6-Minute Walk Test

Twenty-five studies reported 6-minute walk test and data were reported as mean distance (in meters) and standard error. Data are transformed to standard deviation (SD) and meta-analyzed in Figure 8. The effect estimate was 37.81 (95% CI: 20.90, 54.73; p ≤ 0.001) favoring intervention. The heterogeneity is relatively low with I-squared = 14.6% (p=0.255).

Figure 8.

Open in a new tab

Forest plot of 6-minute walk test. CI: confidence intervals.

GRADE: the overall quality of this evidence is judged to be low, downgraded once for risk of bias and once for imprecision.

3.6. Publication Bias

Publication bias was examined using Egger's test in TCM effective rate from 62 studies. The p value is 0.011 (Figure 9), which means there was a small study effect and might influence the interpretation of the summary estimate.

Figure 9.

Open in a new tab

Egger's test for publication bias.

4. Discussion4.1. Summary of Evidence

This systematic review eval‎uates the available evidence in English and Chinese of combining Traditional Chinese medicine (including Chinese herbal medicine and acupuncture) with conventional medicine on treating stable chronic obstructive pulmonary disease patients. Although there is no high-quality evidence identified, we have low-to-moderate quality randomized controlled trials with 8291 participants to suggest that it might be beneficial to incorporate TCM into conventional treatment. This review included 100 double-blinded, randomized controlled trials (8291 participants), with one comparison arm: Chinese herbal medicine plus conventional medicine versus conventional medicine only. The overall risks of bias for these studies are low to unclear. Reasons include (1) unclear reporting of allocation concealment, (2) no detailed information on blinding of participants, personnel, and outcome assessors, and (3) lack of methods reporting how to deal with missing data.

For primary outcomes, there are 40 studies showing the addition of TCM improved the force expiratory volume in 1 s (mean change: 0.18 (L), 95% CI: 0.08, 0.28, I2: 0.0%). But there are few reports about exacerbation rate, only 13 studies were meta-analyzed and the summary effect showed no reduction in acute exacerbation (mean change: −0.29, 95% CI: −0.61, 0.03, I2: 0.0%). There are also limited data (20 studies), suggesting TCM is beneficial by reducing COPD assessment test score (mean change: −2.16, 95% CI: −3.44, −0.88, I2: 0.0%) when compared to conventional medicine only.

Only eight studies reported a total of 10 adverse events, including gastrointestinal symptoms such as nausea, mouth dryness, epigastric discomfort, diarrhea, and respiratory symptoms such as pale yellow phlegm and acute exacerbation with hospitalization. Ten studies were excluded from this review because they did not perform “intention-to-treat” analysis when facing withdrawals. Only one study reported 2 withdrawals in the TCM + CT group and 3 in the CT group, which were mostly lost during treatment. No studies reported adverse effects of either Chinese herbal medicine or acupuncture.

For secondary outcomes, there is limited evidence to show that TCM can improve patients' quality of life, with only 17 studies and different scales used. So we calculated the standardized mean difference and the effect estimate was −0.01 (95% CI: −0.12, 0.10, I2: 0.0%), which did not show any improvement. There are thirty-five studies reporting the change in TCM syndrome score. The symptoms and signs were less severe in the CHM + CT group (mean change: −3.96, 95%CI: -5.41, −2.51, I2 = 0.0%). Merely sufficient evidence (62 studies) showed that TCM was more effective combined with conventional treatment (RR: 0.89, 95% CI: 0.86, 0.93, I2 = 0.0%). The distance walked in 6 minutes was increased by 37.81 meters (95% CI: 20.90, 54.73, I2: 14.6%) in the intervention group when compared to the control group with 25 studies.

GRADE: the outcomes change in FEV1, TCM syndrome score, and effective rate were rated as moderate. This implies there is some confidence in the effect estimate, and the true effect is likely to be close to the estimate of effect, but there is a chance that it is substantially different. Future research is likely to have an important impact on the confidence in the estimate of effect and may change the estimate [40]. The outcomes COPD assessment test, adverse events of any cause, all withdrawals of study participants, and 6-minute walk test were judged to be low-quality evidence. This implies there is limited confidence in the effect estimate and the true effect may be substantially different from the estimate of effect. Future research is very likely to change the estimate of effect or impact the confidence in the estimate of effect [40]. The outcomes exacerbation rate, withdrawals due to a lack of efficacy, and quality of life were rated as very low-quality evidence. This implies there is very little confidence in the effect estimate between types of treatments and the true effect is likely to be substantially different from the estimate of effect. The results of these outcomes are very uncertain and the effect estimate is not accurate enough to recommend any use of Chinese herbal medicine [40]. In summary, the body of evidence suggests that adding Chinese herbal medicine to conventional treatment may be beneficial in stable COPD patients.

4.2. Strengths of This Review

A major strength of this review is we strictly included level 1 evidence of double-blinded RCTs only. This review does not include studies where participants have both acute exacerbated and stable chronic obstructive pulmonary disease and any complicated diseases. Previous systematic reviews report either one single herb extract or formulae, or one specific TCM syndrome-related treatment method [32, 67, 84–91]. However, this is not the usual practice of traditional Chinese medicine. In both outpatient and inpatient settings, TCM uses various formula or acupoints combination according to syndrome differentiation even in the same stable COPD population. This review identifies the add-on effect of any formation of Chinese herbal medicine with different TCM syndromes in comparison with conventional medicine only. This fills the gaps between the normal use of TCM and contemporary research in treating stable COPD patients.

This review identifies the need for high-quality double-blinded randomized controlled trials with more participants in each arm and more detailed reporting of research methods (randomization and blinding of participants and accessors).

4.3. Limitations of This Review

The key methodological limitation to this review was the language restriction, and only Chinese and English literature studies were searched. We believed there were studies written in other languages such as Korean and Japanese, where Chinese herbal medicine and acupuncture were often used. A more comprehensive review might be needed to include all languages.

A second limitation to this review was the broad inclusion criteria of herbal formulae or drugs and treatment duration. This would limit the specificity analysis of a certain herb or formulae, as we generally analyzed CHM as an adjunct treatment to conventional medicine. This might also limit the usage of CHM in clinical situation because we would need a registered Chinese medicine practitioner to diagnose with syndrome differentiation. Subgroup analyses were planned but could not be done in this review as there were too many combinations of herbal drugs and treatment durations. It was unable to investigate whether any of these variables affected treatment efficacy.

A third limitation of this review was lacking studies with sample sizes larger than or equal to 200 participants per arm.

5. Conclusions5.1. Implications for Clinical Practice

Traditional Chinese medicine has been used to treat COPD-related symptoms over decades, yet its effectiveness and safety remain uncertain. Previous clinical studies reported either one single Chinese herbal formulae or one specific Chinese medicine treatment method. Considering there are numerous formulae or combinations of herbs that might be beneficial to stable COPD patients, it is difficult to use current evidence to guide the use of TCM in addition to conventional medicine.

Although we saw some statistical significance in several outcome parameters, it did not mean that there are real treatment effects clinically. Our data suggested that TCM combined with conventional treatment was beneficial in FEV1, COPD assessment test, 6-minute walk distance, and TCM syndrome statistically. Clinicians may consider incorporating TCM into the mainstream medical system with reference to their own clinical experience.

5.2. Implications for Research

High-quality randomized controlled clinical trials or pragmatic trials are needed. In order to provide real information for Chinese medicine practitioners, TCM theories and diagnoses must be taken into account when designing clinical research protocols and conducting trials.

More advanced analyses, like individual participant data and network meta-analysis, can be applied to provide more information on different combinations of herbal drugs and/or acupuncture and generate personalized evidence with reference to TCM theories.

AbbreviationsBOLD:

Burden of Obstructive Lung Diseases

CATTM:

COPD assessment test

CBM:

Chinese Biomedical Database

CENTRAL:

Cochrane Central Register of Controlled Trials

CHM:

Chinese herbal medicine

CI:

Confidence interval

CNKI:

Chinese National Knowledge Infrastructure

COPD:

Chronic obstructive pulmonary disease

CT:

Conventional treatment

FEV1:

Forced expiratory volume in first second

FVC:

Forced vital capacity

GRADE:

Grading of Recommendations, Assessment, Development, and Eval‎uation system

GOLD:

Global Initiative for Chronic Obstructive Lung Disease

ICTRP:

The World Health Organization International Clinical Trials Registry Platform

ITT:

Intention-to-treat

LABA:

Long-acting beta2-agonist

LAMA:

Long-acting anticholinergic

MD:

Mean difference

MeSH:

Medical subject headings

mMRC:

Modified British Medical Research Council

mRCT:

metaRegister of controlled trials

PRISMA-P:

Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols

PROSPERO:

Prospective register of systematic review

QoL:

Quality of life

RCT:

Randomized controlled trial

SABA:

Short-acting beta2-agonist

SABD:

Short-acting bronchodilator

SAMA:

Short-acting anticholinergic

SD:

Standard deviation

SE:

Standard error

SGRQ:

St. George's Respiratory Questionnaire

SMD:

Standardized mean difference

TCM:

Traditional Chinese medicine

VIP:

Chinese Scientific and Technological Periodical Database

WHO:

World Health Organization.

Data Availability

The clinical data used to support the findings of this study are included within the supplementary information files.

Disclosure

This study is part of the MSc dissertation of the first author (K. H. Chan). K. H. Chan is the lead investigator of this project.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors' Contributions

K. H. designed the research protocol, screened databases, extracted data, performed meta-analysis, and wrote the dissertation. Y. Y. S. acted as a second reviewer to screen titles and abstracts for eligibility and extracted data from included studies.

Supplementary Materials

Supplementary Materials

Appendix 1: research protocol. Appendix 2: PRISMA statement reporting standards checklist. Appendix 3: data extraction form. Appendix 4: Cochrane risk of bias tool for randomized controlled trials. Appendix 5: GRADE guidelines. Appendix 6: description of Chinese medicine. Appendix 7: characteristics of excluded studies table.

Click here for additional data file. (113.2KB, docx)

References

• 1.Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;280(9859):2095–2128. doi: 10.1016/S0140-6736(12)61728-0. [DOI] [PMC free article] [PubMed] [Google Scholar]